Switch to:
More From Other Websites
4:53 pm Eli Lilly: FDA extends review period for baricitinib, an investigational Rheumatoid... Jan 16 2017
Top Research Reports for 16th January, 2017 Jan 16 2017
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended Jan 16 2017
No new antidepressants in sight despite growing need, experts warn Jan 16 2017
Eli Lilly is the best stock in pharma: Trader Jan 13 2017
U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment Jan 13 2017
Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference Jan 13 2017
Company News for January 13, 2017 Jan 13 2017
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit Jan 13 2017
US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty Jan 12 2017
US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty Jan 12 2017
Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva Jan 12 2017
Patent Victory Secures Lilly Hold on Cancer Drug Until 2022 Jan 12 2017
Investors in big pharma, biotech look to ride out Trump storm Jan 12 2017
Eli Lilly & Co. : LLY-US: Dividend Analysis : November 15th, 2016 (record date) : By the numbers :... Jan 12 2017
Eli Lilly's stock rallies after appeals court upholds favorable patent ruling Jan 12 2017
Eli Lilly Up 2% in Weak Tape on Positive Ruling Jan 12 2017
U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent Jan 12 2017
Teva loses appeal against Eli Lilly in Alimta patent case Jan 12 2017
Lilly Jumps After Lung Cancer Drug Patent Upheld Jan 12 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK